Response to neoadjuvant therapy with cisplatin in BRCA1-positive breast cancer patients
- Standort
-
Deutsche Nationalbibliothek Frankfurt am Main
- ISSN
-
1573-7217
- Umfang
-
Online-Ressource
- Sprache
-
Englisch
- Anmerkungen
-
online resource.
- Erschienen in
-
Response to neoadjuvant therapy with cisplatin in BRCA1-positive breast cancer patients ; volume:115 ; number:2 ; day:23 ; month:7 ; year:2008 ; pages:359-363 ; date:5.2009
Breast cancer research and treatment ; 115, Heft 2 (23.7.2008), 359-363, 5.2009
- Urheber
-
Byrski, T.
Huzarski, T.
Dent, R.
Gronwald, J.
Zuziak, D.
Cybulski, C.
Kladny, J.
Gorski, B.
Lubinski, J.
Narod, S. A.
- Beteiligte Personen und Organisationen
-
SpringerLink (Online service)
- DOI
-
10.1007/s10549-008-0128-9
- URN
-
urn:nbn:de:101:1-2021081510050304575127
- Rechteinformation
-
Open Access; Der Zugriff auf das Objekt ist unbeschränkt möglich.
- Letzte Aktualisierung
-
14.08.2025, 10:53 MESZ
Datenpartner
Dieses Objekt wird bereitgestellt von:
Deutsche Nationalbibliothek. Bei Fragen zum Objekt wenden Sie sich bitte an den Datenpartner.
Deutsche Nationalbibliothek. Bei Fragen zum Objekt wenden Sie sich bitte an den Datenpartner.
Beteiligte
- Byrski, T.
- Huzarski, T.
- Dent, R.
- Gronwald, J.
- Zuziak, D.
- Cybulski, C.
- Kladny, J.
- Gorski, B.
- Lubinski, J.
- Narod, S. A.
- SpringerLink (Online service)
Ähnliche Objekte (12)
Neoadjuvant therapy with cisplatin in BRCA1-positive breast cancer patients
Neoadjuvant chemotherapy with Cisplatin in BRCA1 mutation carriers – results of treatment
Cisplatin in breast cancer treatment in BRCA1 carriers
Platinum-based neoadjuvant chemotherapy in BRCA1-positive breast cancer: a retrospective cohort analysis and literature review
Why choose the treatment with cisplatin for BRCA1 breast cancers patients?
Neoadjuvant therapy of BRCA1-driven ovarian cancer by combination of cisplatin, mitomycin C and doxorubicin
Toxicity of (neo)adjuvant chemotherapy for BRCA1- and BRCA2-associated breast cancer
Cisplatin as neoadjuvant chemotherapy in triple negative breast cancer: Exciting early results
Results of a phase II open-label, non-randomized trial of cisplatin chemotherapy in patients with BRCA1-positive metastatic breast cancer
Neoadjuvant talazoparib in patients with germline BRCA1/2 mutation-positive, early-stage triple-negative breast cancer: exploration of tumor BRCA mutational status
Prevalence and predictors of loss of wild type BRCA1 in estrogen receptor positive and negative BRCA1-associated breast cancers
HER2-Positive Metaplastic Breast Cancer with Resistance to Neoadjuvant Chemotherapy: Case Report
Neoadjuvant therapy with cisplatin in BRCA1-positive breast cancer patients
Neoadjuvant chemotherapy with Cisplatin in BRCA1 mutation carriers – results of treatment
Cisplatin in breast cancer treatment in BRCA1 carriers
Platinum-based neoadjuvant chemotherapy in BRCA1-positive breast cancer: a retrospective cohort analysis and literature review
Why choose the treatment with cisplatin for BRCA1 breast cancers patients?
Neoadjuvant therapy of BRCA1-driven ovarian cancer by combination of cisplatin, mitomycin C and doxorubicin
Toxicity of (neo)adjuvant chemotherapy for BRCA1- and BRCA2-associated breast cancer
Cisplatin as neoadjuvant chemotherapy in triple negative breast cancer: Exciting early results
Results of a phase II open-label, non-randomized trial of cisplatin chemotherapy in patients with BRCA1-positive metastatic breast cancer
Neoadjuvant talazoparib in patients with germline BRCA1/2 mutation-positive, early-stage triple-negative breast cancer: exploration of tumor BRCA mutational status
Prevalence and predictors of loss of wild type BRCA1 in estrogen receptor positive and negative BRCA1-associated breast cancers
HER2-Positive Metaplastic Breast Cancer with Resistance to Neoadjuvant Chemotherapy: Case Report
Neoadjuvant therapy with cisplatin in BRCA1-positive breast cancer patients
Neoadjuvant chemotherapy with Cisplatin in BRCA1 mutation carriers – results of treatment
Cisplatin in breast cancer treatment in BRCA1 carriers
Platinum-based neoadjuvant chemotherapy in BRCA1-positive breast cancer: a retrospective cohort analysis and literature review
Why choose the treatment with cisplatin for BRCA1 breast cancers patients?
Neoadjuvant therapy of BRCA1-driven ovarian cancer by combination of cisplatin, mitomycin C and doxorubicin
Toxicity of (neo)adjuvant chemotherapy for BRCA1- and BRCA2-associated breast cancer
Cisplatin as neoadjuvant chemotherapy in triple negative breast cancer: Exciting early results
Results of a phase II open-label, non-randomized trial of cisplatin chemotherapy in patients with BRCA1-positive metastatic breast cancer
Neoadjuvant talazoparib in patients with germline BRCA1/2 mutation-positive, early-stage triple-negative breast cancer: exploration of tumor BRCA mutational status
Prevalence and predictors of loss of wild type BRCA1 in estrogen receptor positive and negative BRCA1-associated breast cancers